ArticleApplied health economics and health policy2019

Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.

Ashleigh McGirr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.